COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported Q1 2026 GAAP revenue of $73,000, a 96% decline year-over-year, driven by the absence of a $2.0 million one-time milestone payment received in the prior year. The company posted a GAAP net loss of $3.1 million ($0.23 per share), widening from a $1.5 million loss in Q1 2025, despite reducing operating expenses by approximately 18% through a 50% headcount reduction.
Key figures
- Revenue
- 73000
- Revenue Yoy
- -96.4%
- Headcount reduction
- 50%
- Cash and equivalents
- 4262000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.